Due to the tremendous progress in small-molecule inhibitors targeting tryptophan metabolism, especially IDO and TDO inhibitors in cancer therapy, dual-target inhibitors targeting both IDO1 and TDO are being developed for broader and more effective clinical treatments of various diseases, including M4112 and RY103. The gene discussed is TDO2; the disease is cancer.